

## THE NATIONAL HEALTH SERVICE ACT 2006

### The Pharmaceutical Services (Advanced and Enhanced Services and Emergency Declaration) (England) (Amendment) (No. 3) Directions 2020

The Secretary of State gives the following Directions in exercise of the powers conferred by sections 127, 128, 272(7) and (8) and 273(1) of the National Health Service Act 2006(a).

#### Citation, commencement, application and interpretation

1.—(1) These Directions may be cited as the Pharmaceutical Services (Advanced and Enhanced Services and Emergency Declaration) (England) (Amendment) (No. 3) Directions 2020.

(2) These Directions come into force immediately after they are signed.

(3) These Directions apply in relation to England.

(4) In these Directions “the 2013 Directions” means the Pharmaceutical Services (Advanced and Enhanced Services) (England) Directions 2013(b).

#### Amendment of direction 2 of the 2013 Directions

2.—(1) Direction 2 of the 2013 Directions (interpretation) is amended as follows.

(2) At the appropriate places in the alphabetical order insert—

““coronavirus” has the meaning given in section 1(1) of the Coronavirus Act 2020(c);” and

---

(a) 2006 c. 41. Section 127 has been amended by the Health and Social Care Act 2012 (c. 7) (“the 2012 Act”), Schedule 4, paragraph 64; and section 128 has been amended by the 2012 Act, Schedule 4, paragraph 65.

(b) Signed on 12th March 2013, and amended by: the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2013, signed on 16th September 2013; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 2) Directions 2013, signed on 6th December 2013, which also revoked the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2013; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2014, signed on 12th March 2014; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 2) Directions 2014, signed on 5th December 2014; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2015, signed on 15th September 2015; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2016, signed on 30th August 2016; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No.2) Directions 2016, signed on 30th November 2016; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2017, signed on 29th August 2017; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2018, signed on 8th March 2018; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 2) Directions 2018, signed on 31st August 2018; and the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2019, signed on 13th March 2019, the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 2) Directions 2019, signed on 22nd August 2019; the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 3) Directions 2019, signed on 11th September 2019, the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 4) Directions 2019, signed on 24th October 2019, the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2020, signed on 6th March 2020; the Pharmaceutical Services (Advanced and Enhanced Services and Emergency Declaration) Directions 2020, signed on 27th March 2020; the Pharmaceutical Services (Advanced and Enhanced Services and Emergency Declaration) (Amendment) (England) Directions 2020, signed on 30th June 2020 and the Pharmaceutical Services (Advanced and Enhanced Services and Emergency Declaration) (Amendment) (No.2) (England) Directions 2020, signed on 28th August 2020.

(c) 2020 c. 7.

““Flublok PGD” means a patient group direction authorised by the NHSCB under regulation 233 of the Human Medicines Regulations 2012(a) (exemption for supply etc under a PGD by a person conducting a retail pharmacy business) in respect of Flublok;”.

### **Amendment of directions 7A and 7B of the 2013 Directions**

3.—(1) Directions 7A (Community Pharmacy Seasonal Influenza Vaccination Advanced Service: general matters and preconditions to making arrangements) and 7B(b) (Community Pharmacy Seasonal Influenza Vaccination Service: ongoing conditions for arrangements) are amended as follows.

(2) After “National PGD”, at each place it occurs, insert “or the Flublok PGD”.

### **Amendment of direction 14 of the 2013 Directions**

4.—(1) Direction 14(1) of the 2013 Directions (enhanced services provided by pharmacy contractors) is amended as follows.

(2) After paragraph (b) insert—

- “(ba) a Coronavirus Testing Service, the underlying purpose of which is for P—
- (i) to supply to patients or representatives of patients diagnostic medical devices, or accessories to such devices, to enable the carrying out of tests for coronavirus on the patients,
  - (ii) to carry out tests for coronavirus on patients, or
  - (iii) to take or take in samples from patients or representatives of patients to enable coronavirus tests on those patients to be carried out,
- and to give appropriate advice to patients or representatives of patients about and following such tests;
- (bb) a Coronavirus Vaccination Service, the underlying purpose of which is to provide for the administration of a medicinal product for vaccination or immunisation against coronavirus in accordance with—
- (i) a patient group direction that meets the conditions of regulation 233 of the Human Medicines Regulations 2012(c) (exemption for supply etc under a PGD by a person conducting a retail pharmacy business), or
  - (ii) a protocol that meets the conditions of regulation 247A of the Human Medicines Regulations 2012(d) (protocols relating to coronavirus and influenza vaccinations and immunisations);”.


### **Amendment of the Pharmaceutical Services (Advanced and Enhanced Services and Emergency Declaration) Directions 2020**

5. In direction 2 of the Pharmaceutical Services (Advanced and Enhanced Services and Emergency Declaration) Directions 2020(e) (declaration of emergency requiring the flexible provision of pharmaceutical services), for “30 November 2020” substitute “31 March 2021”.

---

(a) S.I. 2012/1916; the relevant amending instruments are S.I. 2013/235, 2015/1503, 2019/775 and 2020/1125.  
(b) As inserted by direction 8 of the the Pharmaceutical Services (Advanced and Enhanced Services and Emergency Declaration) (England) (Amendment) (No. 2) Directions 2020, signed on 28th August 2020.  
(c) S.I. 2012/1916; the relevant amending instruments are S.I. 2013/235, 2015/1503, 2019/775 and 2020/1125.  
(d) Inserted by S.I. 2020/1125.  
(e) Signed on 27th March 2020. A relevant amendment was made to these Directions by the Pharmaceutical Services (Advanced and Enhanced Services and Emergency Declaration) (Amendment) (No.2) (England) Directions 2020, signed on 28th August 2020.

Signed by authority of the Secretary of State for Health and Social Care

Handwritten signature of Jeannette Howe in black ink.

27<sup>th</sup> November 2020

*Jeannette Howe*  
Head of Pharmacy  
Department of Health and Social Care